Zhaoke Ophthalmology Ltd. has announced that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for NVK002 (Atropine Sulphate Eye Drops 0.02%) for the treatment of myopia progression in children. This acceptance marks a significant step in the regulatory review process for this innovative drug, which is being reviewed as a Class II innovative drug. Previously, an Abbreviated New Drug Application (ANDA) for a 0.01% formulation of the same drug was also accepted by the NMPA. The company aims to address the growing issue of myopia among children and adolescents in China, with this development aligning with the national health objectives outlined by the Chinese government.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief on July 09, 2025, and is solely responsible for the information contained therein.